LENZ Therapeutics (LENZ) investor relations material

Product overview and clinical differentiation

• Developed an eye drop for presbyopia that provides near vision improvement within 10-15 minutes, lasting up to 10 hours for most patients.

• Uses aceclidine, a unique active ingredient that only stimulates the iris sphincter, avoiding the ciliary body and reducing side effects seen in competitors.

• Clinical efficacy at 10 hours surpasses peak efficacy of other products like VUITY and Qlosi, which have shorter duration and limited effectiveness.

• Product approved in August and launched in October, now four to five months into launch.

Competitive landscape

• Only three miotics in the market: aceclidine (exclusive), pilocarpine (VUITY, Qlosi), and carbachol (Tenpoint).

• Pilocarpine-based products have lost market traction due to limited efficacy and short duration; sales forces have been reduced.

• Carbachol targets a narrow population and has similar limitations as VUITY.

• Market opportunity is significant, with 120 million presbyopes in the U.S.

Launch progress and market adoption

• Real-world feedback confirms clinical trial results, with rapid and sustained near vision improvement.

• Early refill rates are encouraging, and sampling strategy is driving trial and conversion to prescriptions.

• Over 6,500 eye care professionals (ECPs) were writing prescriptions by end of Q4, with rapid growth since.

• 80% of prescribers are optometrists, 20% ophthalmologists; strongest uptake in Florida, California, New York, and Texas.